



The Ensign Group, Inc. (ENSG)

Updated June 6th, 2024, by Yiannis Zourmpanos

Key Metrics

Current Price:	\$120	5 Year CAGR Estimate:	7.9%	Market Cap:	\$6.75 B
Fair Value Price:	\$118	5 Year Growth Estimate:	8.0%	Ex-Dividend Date:	06/28/2024 ¹
% Fair Value:	101%	5 Year Valuation Multiple Estimate:	-0.3%	Dividend Payment Date:	07/31/2024 ²
Dividend Yield:	0.2%	5 Year Price Target	\$174	Years Of Dividend Growth:	17
Dividend Risk Score:	A	Retirement Suitability Score:	C	Rating:	Hold

Overview & Current Events

The Ensign Group, Inc. (ENSG) is a healthcare company founded in 1999 and headquartered in San Juan Capistrano, California. The company operates 288 healthcare facilities in 13 states, providing skilled nursing, senior living, rehabilitative care services, and ancillary businesses such as mobile diagnostics and medical transportation. The Ensign Group competes with other healthcare providers in the market. Still, its focus on delivering quality care and creating solid relationships with patients and their families has helped it establish a competitive advantage. The company's revenue segments are divided into four categories: skilled nursing services, assisted living services, home health and hospice services, and other services.

On May 1st, 2024, the company announced results for its first quarter of 2024. ENSG reported non-GAAP EPS of \$1.30 for the period, beating analysts' estimates by \$0.02. In addition, the company reported revenues of \$1.01 billion for the quarter, up 13.9% year-over-year.

Additionally, GAAP net income improved 15.0% to \$68.8 million, and adjusted net income increased 16.6% to \$75.4 million. Year-over-year consolidated GAAP and adjusted revenues rose 13.9% to \$1.01 billion. Improved Same Facilities and Transitioning Facilities occupancy rates by 2.7% to 81.0% for the Same Facilities and 3.1% for the Transitioning Facilities. The managed care census for the Same Facilities was up 4.8%, and Transitioning Facilities was up 27.8%. Similarly, skilled services revenue of \$969.6 million grew 13.9% yearly, while the Standard Bearer segment grew 12.6% to \$22.2 million.

Finally, the company also reaffirmed its fiscal 2024 earnings target of between \$5.29 and \$5.47 per share. Revenue is expected to range from \$4.17 billion to \$4.13 billion, against a consensus of \$4.15 billion.

Growth on a Per-Share Basis

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2029
EPS	\$0.78	\$1.06	\$0.83	\$0.91	\$1.70	\$1.64	\$3.06	\$3.42	\$3.95	\$3.65	\$5.38	\$7.90
DPS	\$0.14	\$0.15	\$0.16	\$0.17	\$0.18	\$0.19	\$0.20	\$0.21	\$0.22	\$0.23	\$0.24	\$0.31
Shares³	45.2	51.4	51.9	51.4	52.6	53.5	54.6	55.2	55.7	55.7	56.2	59.1

Notwithstanding the macro environment, growth was robust, and occupancy rates returned to levels before the pandemic. Ensign Group is well financed to continue supporting its growth efforts, and we saw that the tail of its asset returns continues to generate value. However, as earnings normalize and reach pre-pandemic levels, there is less room for growth, and we have assumed an annual EPS growth rate of 8.0% through 2029. We revised our EPS estimate for 2024, matching the midpoint of management's estimates at \$5.38. In addition, DPS has consistently increased for the last 17 years, and we remain confident that the company can keep on this track. We expect the company's DPS to grow slightly slower than its EPS at 5.0% through 2029, in line with its long-term averages.

¹ The ex-dividend date is estimated based on historical data.

² The dividend payment date is estimated based on historical data.

³ In millions.

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



The Ensign Group, Inc. (ENSG)

Updated June 6th, 2024, by Yiannis Zourmpanos

Valuation Analysis

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	Now	2029
Avg. P/E	18.7	20.1	23.6	21.5	18.8	28.7	16.8	24.1	21.3	26.4	22.3	22.0
Avg. Yld.	1.0%	0.7%	0.8%	0.9%	0.6%	0.4%	0.4%	0.3%	0.3%	0.2%	0.2%	0.2%

ENSG has attracted a relatively high P/E multiple in the past couple of years, and the stock is trading at a forward P/E of 22.3, higher than its 10-year and five-year averages of 22.0 and 23.5, respectively. However, considering the growth prospects, we believe that a P/E of 22.0 accurately reflects the risk/reward of the stock, which leads to our estimated fair value of the company at \$174 by 2029.

Safety, Quality, Competitive Advantage, & Recession Resiliency


Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2029
Payout	18%	14%	19%	19%	11%	12%	7%	6%	6%	6%	4%	4%

The Ensign Group's distinctive business model, which focuses on buying and renovating troubled healthcare facilities to restore performance and profitability, gives them a competitive advantage. In addition, the organization has performed well during recessions thanks to its solid financial position and capacity to adapt to the evolving healthcare market. Even though Ensign Group has a debt-to-equity ratio of 1.22, which is lower than the industry norm, it is still considered high. However, the company's cash reserve stands at \$511.8 million compared to its long-term debt of \$144.5 million, and its strong operating cash flow of \$363.63 million supports a favorable leverage profile.

Final Thoughts & Recommendation

We remain confident in The Ensign Group's prospects, as its outlook is still favorable, with strong growth ahead. However, we maintain our hold rating, premised upon the 7.9% annualized total returns for the medium-term, derived from the forecasted earnings-per-share growth of 8.0%, the 0.2% dividend yield, and a valuation headwind.

Total Return Breakdown by Year



Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



The Ensign Group, Inc. (ENSG)

Updated June 6th, 2024, by Yiannis Zourmpanos



The Ensign Group, Inc. (ENSG)

Updated June 6th, 2024, by Yiannis Zourmpanos

Income Statement Metrics

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Revenue	1,027	1,342	1,655	1,598	1,755	2,037	2,403	2,627	3,025	3,729
Gross Profit	156	185	188	173	219	291	407	468	518	591
Gross Margin	15.2%	13.8%	11.4%	10.8%	12.5%	14.3%	17.0%	17.8%	17.1%	15.8%
SG&A Exp.	57	64	69	74	91	111	130	152	159	263
D&A Exp.	26	28	39	42	45	51	55	56	62	72
Operating Profit	73	93	81	57	83	129	223	260	297	255
Op. Margin	7.1%	6.9%	4.9%	3.5%	4.7%	6.3%	9.3%	9.9%	9.8%	6.8%
Net Profit	36	55	50	40	92	111	170	195	225	209
Net Margin	3.5%	4.1%	3.0%	2.5%	5.3%	5.4%	7.1%	7.4%	7.4%	5.6%
Free Cash Flow	31	(27)	8	25	159	121	323	206	185	270
Income Tax	27	35	33	14	13	24	46	60	64	63

Balance Sheet Metrics

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Total Assets	494	748	1,001	1,102	1,182	2,362	2,546	2,851	3,452	4,178
Cash & Equivalents	50	42	58	42	31	59	237	262	316	510
Acc. Receivable	130	209	244	265	252	309	305	329	408	485
Goodwill & Int.	78	105	122	139	83	61	61	67	83	83
Total Liabilities	236	321	541	602	580	1,706	1,727	1,829	2,203	2,680
Accounts Payable	33	36	39	39	40	45	51	58	77	93
Long-Term Debt	68	100	284	313	243	328	116	157	153	149
Total Equity	259	427	456	492	591	654	818	1,021	1,247	1,492
LTD/E Ratio	0.26	0.23	0.62	0.64	0.41	0.50	0.14	0.15	0.12	0.10

Profitability & Per Share Metrics

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Return on Assets	5.7%	8.9%	5.7%	3.8%	8.1%	6.2%	6.9%	7.2%	7.1%	5.5%
Return on Equity	11.7%	16.2%	11.3%	8.5%	17.1%	17.8%	23.2%	21.2%	19.8%	15.3%
ROIC	7.6%	13.0%	7.9%	5.2%	11.1%	12.1%	17.8%	18.4%	17.4%	13.7%
Shares Out.	45.2	51.4	51.9	51.4	52.6	53.5	54.6	55.2	55.7	57.3
Revenue/Share	22.24	25.70	31.74	30.25	32.26	36.38	43.07	46.16	53.20	65.06
FCF/Share	0.68	(0.51)	0.16	0.48	2.93	2.16	5.79	3.62	3.25	4.72

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.